Previous Close | 15.25 |
1-Year Change | -11.39% |
6-Months Change | -39.7% |
3-Months Change | -46.04% |
Moving Avg (50d) | 23.426 |
Moving Avg (200d) | 23.589 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 1.25B |
Beta (3-Years) | 1.39 |
Revenue Growth (ttm) | 11.04% |
Net Profit Margin (ttm) | -37.36% |
Return On Assets (ttm) | -23.88% |
EPS (ttm) | -3.36 |
PE Ratio (ttm) | -4.54 |
Dividend Yield | % |
Asset Description: | Myriad Genetics, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Strong sell |
Forecast Date: | 2024-11-01 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
15.606 | 16.065 | 16.371 | 16.83 | 17.595 | 18.36 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Life Sciences Tools & Services |
Country: | United States |